GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Momenta Pharmaceuticals Inc (NAS:MNTA) » Definitions » PB Ratio

Momenta Pharmaceuticals (Momenta Pharmaceuticals) PB Ratio : 15.75 (As of Apr. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Momenta Pharmaceuticals PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-25), Momenta Pharmaceuticals's share price is $52.48. Momenta Pharmaceuticals's Book Value per Share for the quarter that ended in Jun. 2020 was $3.33. Hence, Momenta Pharmaceuticals's PB Ratio of today is 15.75.

Warning Sign:

Momenta Pharmaceuticals Inc stock PB Ratio (=15) is close to 10-year high of 15

The historical rank and industry rank for Momenta Pharmaceuticals's PB Ratio or its related term are showing as below:

MNTA' s PB Ratio Range Over the Past 10 Years
Min: 1.44   Med: 2.99   Max: 15
Current: 15

During the past 13 years, Momenta Pharmaceuticals's highest PB Ratio was 15.00. The lowest was 1.44. And the median was 2.99.

MNTA's PB Ratio is not ranked
in the Drug Manufacturers industry.
Industry Median: 1.945 vs MNTA: 15.00

During the past 12 months, Momenta Pharmaceuticals's average Book Value Per Share Growth Rate was 5.60% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -10.90% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -0.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 4.20% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Momenta Pharmaceuticals was 54.30% per year. The lowest was -27.70% per year. And the median was 6.30% per year.

Back to Basics: PB Ratio


Momenta Pharmaceuticals PB Ratio Historical Data

The historical data trend for Momenta Pharmaceuticals's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Momenta Pharmaceuticals PB Ratio Chart

Momenta Pharmaceuticals Annual Data
Trend Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.77 2.88 2.85 2.36 5.06

Momenta Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.93 4.64 5.06 7.47 9.98

Competitive Comparison of Momenta Pharmaceuticals's PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Momenta Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Momenta Pharmaceuticals's PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Momenta Pharmaceuticals's PB Ratio distribution charts can be found below:

* The bar in red indicates where Momenta Pharmaceuticals's PB Ratio falls into.



Momenta Pharmaceuticals PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Momenta Pharmaceuticals's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Jun. 2020)
=52.48/3.333
=15.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Momenta Pharmaceuticals  (NAS:MNTA) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Momenta Pharmaceuticals PB Ratio Related Terms

Thank you for viewing the detailed overview of Momenta Pharmaceuticals's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Momenta Pharmaceuticals (Momenta Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While a biosimilar version of Eylea is in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including nipocalimab, M254, and M230, are in development to treat rare autoimmune diseases.
Executives
Bruce Downey director
Alejandra Carvajal officer: Chief Legal Officer C/O CERULEAN PHARMA INC., 840 MEMORIAL DRIVE, 5TH FLOOR, CAMBRIDGE MA 02139
Jose-carlos Gutierrez-ramos director C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Elizabeth Stoner director C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE MA 02142
Santiago Arroyo officer: SVP, Chief Medical Officer C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Young Kwon officer: Chief Financial & Bus. Officer C/O MOMENTA PHARMACEUTICALS INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Ian Fier officer: Chief Mfg and Program Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Jo Ann Beltramello officer: Chief HR and Inf. Officer C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Jane F Barlow director 6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Anthony M. Manning officer: Chief Scientific Officer C/O PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Donna Roy Grogan director 1133 OLD QUEEN ANNE ROAD, CHATHAM MA 02633
Agnieszka Cieplinska officer: Chief Accounting Officer (PAO) C/O MOMENTA PHARMACEUTICALS, INC. 301 BINNEY STREET CAMBRIDGE MA 02142
Craig A Wheeler director, officer: President & CEO

Momenta Pharmaceuticals (Momenta Pharmaceuticals) Headlines

From GuruFocus

Momenta Provides Corporate Update Amid COVID-19 Pandemic

By Marketwired Marketwired 04-02-2020